UCB, Inc.

UCB, Inc.
Share

UCB, Inc.

 •  April 26

UCB will bring first electronic injection device to rheumatology patients in EU Brussels, Belgium – April 26, 2017 – UCB has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the CIMZIA dose dispenser cartridge for use with the re-usable ava® electronic injection device in...

UCB, Inc.

 •  March 6

Results presented at the American Academy of Dermatology (AAD) Annual Meeting 1 These data represent important new information for patients and physicians making treatment decisions, given that disease onset for autoimmune conditions often coincides with women’s peak reproductive years and only limited published data on transfer of biologics into...

UCB, Inc.

 •  March 4

Late-breaking, investigational 16-week data presented from the CIMPASI-1 and CIMPASI-2 trials showing CIMZIA demonstrated statistically and clinically significant improvements for patients with moderate-to-severe chronic plaque psoriasis Four-year data from the CIMZIA RAPID-PSA study showing long-term maintenance of improvement in the joint and...

UCB, Inc.

 •  November 15, 2016

While the primary endpoints of superiority of Cimzia® over Humira® were not demonstrated in EXXELERATE, data generated suggest for the first time the benefits of switching to a second anti-TNF (Cimzia® or Humira®), even in primary TNF-failure patients Comparable safety between Cimzia® and Humira® was observed across two years, including in patients...

UCB, Inc.

 •  October 20, 2016

October 20th is World Osteoporosis Day - a chance to raise awareness of a condition that can cause significant pain and reduce people’s quality of life.
Like other chronic diseases, such as hypertension and hyperlipidaemia, osteoporosis is typically asymptomatic until a fracture occurs - thus it’s often called a "silent disease".
However, from that...

UCB, Inc.

 •  October 3, 2016

People with rheumatoid arthritis (RA) are at higher risk for cardiovascular and muscle problems. That is why UCB developed the Wellness 4U activity tracker - a pilot programme that encourages healthy behaviours.
Wellness 4U is a comprehensive, web-based health and wellness programme that uses a wearable activity tracker to help promote physical...

UCB, Inc.

 •  October 3, 2016

Topline results from the first of three Phase 3 trials in psoriasis clinical development program Brussels, Belgium and Menlo Park, Calif., October 3, 2016 — UCB (Euronext: UCB) and Dermira, Inc. (NASDAQ: DERM) today announced topline results from CIMPASI-2, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the efficacy and...

UCB, Inc.

 •  September 26, 2016

BRUSSELS, BELGIUM and THOUSAND OAKS, Calif. (September 26, 2016 - 10 PM CET) – UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for romosozumab, an investigational monoclonal antibody for the treatment of...

UCB, Inc.

 •  September 19, 2016

Brussels, Belgium – September 19, 2016 – UCB has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the use of CIMZIA® AutoClicks® Prefilled Pen in all approved indications. The positive opinion was based on validated data and risk benefit analysis for the AutoClicks®...

UCB, Inc.

 •  September 18, 2016

FRAME Data Simultaneously Published in New England Journal of Medicine and Presented at ASBMR Showed Treatment With Romosozumab Significantly Reduced New Vertebral and Clinical Fractures Through 12 Months Significant Bone Mineral Density Gains Shown at Six and 12 Months at the Lumbar Spine, Total Hip and Femoral Neck Bone Mineral Density Continued...